Biotech's Proprietary Tech. May Lead to New Treatments for Cancer
ROCHESTER, NY / ACCESSWIRE / March 24, 2015 / Ticker Research, a stock market research firm focused on the small cap and microcap sectors, announced today that it has released a new report on PharmaCyte Biotech, Inc.. (PMCB), a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R).
To view or download the free report, please visit:
http://tickerresearch.com/wp-content/uploads/2015/03/TickerResearch-PMCB_Research_Report_March_24.pdf
Below is an excerpt from Ticker Research's report:
"Perhaps the biggest potential breakthrough for PharmaCyte is the use of their Cell-in-a-Box technology on pancreatic cancer. PharmaCyte owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the chemotherapy drug ifosfamide.
After being awarded the U.S. Food and Drug Administration's (FDA) Orphan Drug designation, PharmaCyte can now take direct aim at becoming the treatment of choice for advanced pancreatic cancer. The 'FDA Orphan Drug' designation validates the technology and brings with it special assistance from the FDA in the development of the drug and up to seven additional years of marketing exclusivity in the U.S. if it makes it to market, in addition to possible exemptions or reductions in regulatory fees and taxes.
PharmaCyte will begin testing their solution head to head vs. head in the Stage 2b Clinical trials vs. the industry standard treatment (Which is Gemcitabine, sold under the brand name Gemzar(™) by Eli Lilly, combined with Celgene's Abraxane).
Positive results would be a major development for the company and its investors.
With small cap biotechnology stocks leading the markets PharmaCyte could be the next major biotech winner, and therefore requires your immediate attention."
The sector has seen big moves over the last few weeks as investors have been snapping up shares of little known biotechs, a couple examples of movers we've seen:
Oramed Pharmaceuticals (ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems.
Cytori Therapeutics, Inc. (CYTX), a late stage cell therapy company developing laboratory equipment and autologous cell therapies from adipose tissue to treat a variety of medical conditions, is another biotech leader.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). For more information please visit http://www.pharmacytebiotech.com
About Ticker Research:
Ticker Research produces sponsored research reports and articles for microcap companies.Ticker Research has been compensated for the writing and release of this report. This Ticker Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures and disclaimers before investing. Ticker Research is not a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.tickerresearch.com.
Ticker Research
info@tickerresearch.com
SOURCE: Ticker Research
